Value
4.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 4.0 |
COAG · Why this verdict
Why Hemab Therapeutics Holdings, In (COAG) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Hemab Therapeutics shows unusually heavy, broad-based insider buying and an attractive valuation against its analyst target, but a thin risk-reward gap that fails the engine's own gate, quality below the investability floor, and a purely speculative small-cap classification keep conviction and position sizing at essentially zero.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Insiders have been heavy net buyers, purchasing $55.46 million of stock (3.83% of market cap) across 16 transactions with zero sells over the past 90 days, driving a bullish insider signal. Insider breakdown | Insider buying should continue or at least not reverse into net selling, with the bullish signal holding over the next 12 months. | →Stable |
| CounterHeavy insider buying in a single-asset biotech can reflect a few insiders' outsized personal conviction in a binary clinical outcome rather than a broadly diversifiable investment signal. | ||
Value scores attractively at 7.5, with analyst targets implying 16.2% upside to a take-profit level of $36.02 from a $31.00 current price. Valuation breakdown | The value score should hold near current levels and price should progress toward the analyst target over the next 12 months. | →Stable |
| CounterValue confidence is only 0.33, so the 'attractive' read leans heavily on a single analyst-target component for a pre-commercial biotech company. | ||
The engine's asymmetry gate failed, with a risk-reward ratio of 1.08 against a 1.5 minimum threshold, reflecting nearly matched upside (16.2%) and downside (15.0%). Engine gate (failed) | For the setup to clear the gate, the asymmetry ratio needs to climb above 1.5 as upside expands or downside risk narrows over the next 12 months. | →Stable |
| CounterHeavy, broad-based insider buying at current prices suggests insiders may see meaningfully more upside than the modeled 16.2%, which would improve the risk-reward profile beyond what the gate currently captures. | ||
Quality sits below the engine's investability floor at 2.4 versus a 4.0 minimum, driven by the absence of a competitive moat, consistent with a pre-revenue biotech profile. Quality breakdown | Quality should rise above the 4.0 floor as the company demonstrates a path toward margins or a durable moat over the next 12 months. | →Stable |
| CounterA current ratio of 5 and a Piotroski F-score of 4.4, a middling rather than worst-case reading, suggest the balance sheet has more resilience than the quality score alone implies. | ||
The engine's edge derives from the stock's small size ($1.4B market cap) sitting below institutional reach, but the position is classified purely speculative given the binary nature of biotech outcomes, keeping conviction at none. Edge rationale | As market capitalization grows or clinical catalysts materialize, conviction should move up from none over the next 12 months. | →Stable |
| CounterThe very heavy and broad-based insider buying, spread across 16 separate transactions, cuts against the 'no confidence' implication of a none-conviction, speculative classification. | ||
Insiders have been heavy net buyers, purchasing $55.46 million of stock (3.83% of market cap) across 16 transactions with zero sells over the past 90 days, driving a bullish insider signal.
→StableInsider breakdown
- Expectation
- Insider buying should continue or at least not reverse into net selling, with the bullish signal holding over the next 12 months.
CounterHeavy insider buying in a single-asset biotech can reflect a few insiders' outsized personal conviction in a binary clinical outcome rather than a broadly diversifiable investment signal.
Value scores attractively at 7.5, with analyst targets implying 16.2% upside to a take-profit level of $36.02 from a $31.00 current price.
→StableValuation breakdown
- Expectation
- The value score should hold near current levels and price should progress toward the analyst target over the next 12 months.
CounterValue confidence is only 0.33, so the 'attractive' read leans heavily on a single analyst-target component for a pre-commercial biotech company.
The engine's asymmetry gate failed, with a risk-reward ratio of 1.08 against a 1.5 minimum threshold, reflecting nearly matched upside (16.2%) and downside (15.0%).
→StableEngine gate (failed)
- Expectation
- For the setup to clear the gate, the asymmetry ratio needs to climb above 1.5 as upside expands or downside risk narrows over the next 12 months.
CounterHeavy, broad-based insider buying at current prices suggests insiders may see meaningfully more upside than the modeled 16.2%, which would improve the risk-reward profile beyond what the gate currently captures.
Quality sits below the engine's investability floor at 2.4 versus a 4.0 minimum, driven by the absence of a competitive moat, consistent with a pre-revenue biotech profile.
→StableQuality breakdown
- Expectation
- Quality should rise above the 4.0 floor as the company demonstrates a path toward margins or a durable moat over the next 12 months.
CounterA current ratio of 5 and a Piotroski F-score of 4.4, a middling rather than worst-case reading, suggest the balance sheet has more resilience than the quality score alone implies.
The engine's edge derives from the stock's small size ($1.4B market cap) sitting below institutional reach, but the position is classified purely speculative given the binary nature of biotech outcomes, keeping conviction at none.
→StableEdge rationale
- Expectation
- As market capitalization grows or clinical catalysts materialize, conviction should move up from none over the next 12 months.
CounterThe very heavy and broad-based insider buying, spread across 16 separate transactions, cuts against the 'no confidence' implication of a none-conviction, speculative classification.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 2.9 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 4.5 |
- ▸Overbought bear rally (RSI 71)
- ▸Volume accumulation (rising OBV)
Sentiment
6.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.3 |
| Price target | 5.5 |
| erm sentiment | 5.5 |
- ▸Light analyst coverage (5.0) — signal dampened
Insider
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $55,460,171 (2.404% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.1 |
| support resistance | 1.6 |
| 52w position | 8.5 |
Risk (lower is worse)
4.9/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 4.7 |
| volatility | 0.0 |
| debt equity | 10.0 |
Catalyst
5.0/10data confidence 25%| Component | Sub-score |
|---|---|
| erm | 5.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:7.0>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.7=NEGATIVE
Warning (0)
none
Reward-to-Risk
-0.66
Upside
-9.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the ASYMMETRY gate's -0.7=NEGATIVE outcome against Insider at 8.5 and asymmetric R:R of -0.66.
The strongest dimensions are Insider at 8.5, Momentum at 7.0, and Sentiment at 6.2; the weakest are Quality at 2.5, Technical at 3.7, and Value at 4.0. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of -0.66 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Broad Based Insider Buying
Trip ifNet insider selling exceeds $5 million over a 90-day window, reversing the current bullish signal.
- P2Attractive Valuation Vs Analyst Target
Trip ifAnalyst-target upside compresses below 5% from the current 16.2%.
- P3Failed Asymmetry Gate
Trip ifAsymmetry ratio rises above 1.5, clearing the engine's gate from the current 1.08 reading.
- P4Quality Below Investability Floor
Trip ifQuality score rises above 4.0 from the current 2.4.
- P5Small Cap Edge With Speculative Sizing
Trip ifMarket capitalization exceeds $3 billion, moving the stock into institutional reach and invalidating the small-cap edge rationale.